Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma.
This prospective randomized trial evaluated the effect of DTIC and interferon as adjuvant therapy for high risk stage 1 malignant melanoma in 26 patients. Both groups were well matched for depth of disease, site of melanoma and other prognostic criteria. Like other studies the findings of 2.6 times increased relative risk of mortality in the treatment arm do not support a rationale for adjuvant immuno-chemotherapy even in patients at high risk of recurrence.
Kerin
M J
MJ
Department of Clinical Surgery, Meath/Adelaide Hospitals, Dublin, Ireland.
Gillen
P
P
Monson
J R
JR
Wilkie
J
J
Keane
F B
FB
Tanner
W A
WA
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D003606:Dacarbazine; D007372:Interferons